Rolando Cimaz

TL;DR: In this article, the authors investigated the drug retention rate of interleukin (IL)-1 inhibitors on systemic JIA (sJIA) patients and evaluated predictive factors of drug survival based on data from a real-world setting concerning sJIA.

TL;DR: These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.

TL;DR: Anakinra treatment is effective in SJIA, at least in the short term, and is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature.

TL;DR: Benefits of anti-inflammatory, immunosuppressive and biological drugs during pregnancy and lactation, effects of these drugs on male and female fertility and possible long-term effects on infants exposed to drugs antenatally are discussed.

TL;DR: It is demonstrated that aberrant sensing of nucleic acids can cause immune upregulation and heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state.